Use of live attenuated influenza vaccines in young children in resource-poor settings

The Lancet Global Health

Volumn 4, Issue 12, 2016, Pages e879-e880

  Isakova Sivak, Irina ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; LIVE VACCINE;

CHILD; CHILDHOOD MORTALITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE STATUS; IMMUNOGENICITY; INFLUENZA A VIRUS (H1N1); INFLUENZA VACCINATION; MORBIDITY; NOTE; PRIORITY JOURNAL; SHELF LIFE; VIRUS INFECTIVITY; VULNERABLE POPULATION; WORLD HEALTH ORGANIZATION; HEALTH CARE PLANNING;

CHILD; HEALTH RESOURCES; HUMANS; INFLUENZA VACCINES; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84991258611     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(16)30247-9     Document Type: Note

References (10)

1. 1 Rudenko, L, van den Bosch, H, Kiseleva, I, et al. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 29:suppl 1 (2011), A40–A44.
2. 2 Rudenko, L, Yeolekar, L, Kiseleva, I, Isakova-Sivak, I, Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: process challenges and success stories. Vaccine 34 (2016), 5436–5441.
3. 3 Brooks, WA, Zaman, K, Lewis, KDC, et al. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health, 2016 published online Oct 13. http://dx.doi.org/10.1016/S2214-109X(16)30200-5.
4. 4 Victor, JC, Lewis, KDC, Diallo, A, et al. Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health, 2016 published online Oct 13. http://dx.doi.org/10.1016/S2214-109X(16)30201-7.
5. 5 Ortiz, JR, Goswami, D, Lewis, KD, et al. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh. Vaccine 33 (2015), 3415–3421.
6. 6 Cotter, CR, Jin, H, Chen, Z, A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS pathogens, 10, 2014, e1003831.
7. 7 Flannery, B, Chung, J, Influenza vaccine effectiveness, including LAIV vs IIV in children and adolescents, US Flu VE Network, 2015–16. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-06/influenza-05-flannery.pdf, June 22, 2016 (accessed Sept 26, 2016).
8. 8 Flannery, B, Chung, J, Influenza vaccine effectiveness in adults and children in primary care in the UK: provisional end-of-season results 2015–16. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/530756/Influenza_vaccine_effectiveness_in_primary_care_in_children.pdf, June, 2016 (accessed Sept 26, 2016).
9. 9 Chambers, C, Skowronski, DM, Sabaiduc, S, et al. Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. Euro Surveill, 21, 2016, 30168.
10. 10 Nohynkek, H, Baum, U, Syrjänen, R, Ikonen, N, Sundman, J, Jokinen, J, Effectiveness of the live attentuated and the inactivated influenza vaccine in two-year-olds—a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill, 2016, 10.2807/1560-7917.ES.2016.21.38.30346 published online Sept 22.